Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Effect of Different Bioactive Restorative Materials and Techniques on Pulpal Condition

15 luglio 2026 aggiornato da: Dina Ashraf

Restorative materials play a crucial role in dental treatments, particularly in managing tooth decay and restoring damaged teeth. Their interaction with dental pulp is significant, especially in cases where pulp inflammation is present.

When a tooth is compromised, the choice of restorative material can influence the health of the pulp. Certain materials can promote healing and reduce inflammation, while others may exacerbate the condition. For instance, biocompatible materials like glass ionomer or resin-modified glass ionomer have been shown to provide a favorable environment for pulp cells, potentially aiding in the regeneration of dental pulp tissue.

Conversely, materials that are not well-tolerated may lead to further irritation and inflammation, highlighting the importance of selecting appropriate restorative materials to protect pulp vitality and support overall dental health.

Panoramica dello studio

Stato

Completato

Descrizione dettagliata

Different filling materials can significantly influence pulp inflammation, making their selection crucial in restorative dentistry. For instance, traditional amalgam, while robust and durable, may lead to pulp irritation due to its thermal properties and the potential for mercury release, which can trigger inflammatory responses in the surrounding tissue.

Composite resins offer better aesthetics and adhesion but can induce inflammation if not properly cured or if components such as unpolymerized monomers leach into the pulp. Glass ionomer materials, favored for their fluoride release and ability to bond to dentin, generally result in less inflammation and can aid in remineralization; however, their mechanical properties may limit their application in posterior teeth.

Emerging materials, such as biocompatible resin-modified glass ionomers and bioactive materials, aim to minimize pulp inflammation while promoting healing through their inherent chemical properties. Therefore, understanding the interactions between these materials and dental pulp is essential for optimizing restorative outcomes and ensuring patient comfort and health.

Pulp inflammation is closely associated with the release of cytokines, which are crucial mediators in the inflammatory response. When dental pulp tissue is injured or infected, immune cells are activated, leading to the secretion of pro-inflammatory cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). These cytokines play a significant role in recruiting additional immune cells to the site of inflammation, enhancing the inflammatory response and promoting pain. Elevated levels of these cytokines can lead to chronic inflammation, which may further damage pulp tissue and compromise its vitality. Conversely, anti-inflammatory cytokines like interleukin-10 (IL-10) can help regulate this response and promote healing.

The balance between pro-inflammatory and anti-inflammatory cytokines is critical; dysregulation can result in prolonged inflammation and can influence the outcomes of dental treatments.Understanding this relationship is vital for developing therapeutic strategies aimed at managing pulp inflammation and preserving dental health.

Evaluating pulp inflammation through interstitial cervical fluid presents a promising approach for diagnosing and monitoring pulpal health. Interstitial cervical fluid, found in the periodontal tissues around the teeth, can serve as a biochemical marker for inflammatory processes occurring within the dental pulp. When pulp inflammation occurs, cytokines and other inflammatory mediators are released into the surrounding tissues, leading to alterations in the composition of this fluid. By analyzing the levels of specific biomarkers, such as pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) or enzymes like matrix metalloproteinases, clinicians can gain insights into the extent and nature of pulpal inflammation.

This non-invasive method allows for a more nuanced understanding of the inflammatory status of the pulp, enabling timely interventions and more tailored treatment strategies. As research advances, the use of interstitial cervical fluid analysis could become a valuable tool in clinical dentistry for assessing pulpal health and guiding therapeutic decisions.

The methodology for testing interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α) in intracervical fluids typically involves several key steps to ensure accurate measurement of these inflammatory cytokines. First, cervical fluid samples are collected through a minimally invasive procedure, ensuring sterility to avoid contamination.

Following collection, the samples are processed promptly, often by centrifugation, to remove cellular debris. The supernatant is then stored at low temperatures until analysis. Quantification of IL-1 and TNF-α is usually performed using enzyme-linked immunosorbent assay (ELISA), which allows for sensitive and specific detection of these cytokines. The assay involves adding specific antibodies that bind to the target cytokines in the samples, followed by a secondary antibody conjugated to an enzyme.

A genuinely novel substitute for traditional amalgam filling materials is the bioactive powder-liquid filler. Its remarkable endurance, high flexural strength, natural-looking appearance, and bioactive ion release are its defining characteristics. Cention Forte aids in remineralization and demineralization prevention. An advanced ion-releasing mechanism is present in this unique filler substance.

Cention Forte will release hydroxide ions as needed to assist restore pH balance and stop the demineralization of tooth structure if the pH falls as a result of the growth of cariogenic bacteria. In addition, the calcium and fluoride ions that Cention Forte releases can help to prevent secondary cavities and remineralize the toothstructure. Cention Forte and Cention Primer are a well-coordinated system.

Using pre-reacted glass-ionomer technology, surface pre-reacted glass-ionomer (SPRG) filler was created to give restorative materials bioactive properties. Aluminum (Al3+), borate (BO33-), sodium (Na+), silicate (SiO32-), strontium (Sr2+), and fluoride (F-) are the six ions that can be released by the fluoraluminosilicate glass and polyacrylic acid solution that make up SPRG filler. These many ions have the power to give enamel acid resistance and stop demineralization [4,6]. Additionally, research has shown that the ions generated by SPRG may have antibacterial properties, however they are only partially effective in preventing the formation of biofilms or bacterial adhesion

Tipo di studio

Interventistico

Iscrizione (Effettivo)

30

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Abbasia
      • Cairo, Abbasia, Egitto
        • Ain shams university hospitals

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Simple occlusal deep carious lesions.
  • ICDAS 5 and 6.
  • No restorations with the related teeth.
  • Periodontally healthy patient (no bleeding on probing and no radiographic evidence of periodontal bone loss)
  • Normal occlusion.
  • Participants willing to commit for the entire period of the trial and agreed to sign the written consent after full explanation of the study.

Exclusion Criteria:

  • Vulnerable groups such as pregnant females, breast feeding, prisoners, mentally ill, etc.…
  • Cigarette smoking or any form of tobacco consumption.
  • Medically compromised patients as diabetes.
  • A previously endo treated teeth.
  • Ongoing dental or periodontal treatment 12 months before the beginning of the study.
  • Presence of periodontal pockets >3 mm in the affected tooth.
  • Antibiotics or any medication that might lead to decreased salivary flow.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Surface pre-reacted glass ionomer based injectable composite
Restoring molar tooth with class 1 cavity ICDAS score 5 & 6 with Surface pre-reacted glass ionomer based injectable composite 10 patient per group
To evaluate the effect of different restorative materials used in deep cavities effect on gingival crevicular fluid inflammatory cytokine levels
Altri nomi:
  • Tecniche
Comparatore attivo: Resin modified glass ionomer
Restoring molar tooth with class 1 cavity ICDAS score 5 & 6 with Resin modified glass ionomer 10 patient per group
To evaluate the effect of different restorative materials used in deep cavities effect on gingival crevicular fluid inflammatory cytokine levels
Altri nomi:
  • Tecniche
Comparatore attivo: Cention forte
Restoring molar tooth with class 1 cavity ICDAS score 5 & 6 with Cention forte 10 patient per group
To evaluate the effect of different restorative materials used in deep cavities effect on gingival crevicular fluid inflammatory cytokine levels
Altri nomi:
  • Tecniche

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Measuring Pulpal inflammatory responses
Lasso di tempo: 1 month
(Analysis of the crevicular fluid) (TNF Alpha & IL1) after using two different filling materials and techniques.
1 month

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Post-operative pain
Lasso di tempo: 1 to 6 days
Participants will be evaluated for postoperative pain using a Visual Analog Scale (VAS) immediately, after restoration, 1 day and 6 days post-treatment and Pain scores will be collected and categorized as mild (1-3), moderate (4-6), or severe (7-10).
1 to 6 days

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Cattedra di studio: Medhat Taha EL-Faramawy, M.D, Professor of Endodontics, Faculty of Dentistry, Ain shams University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

15 marzo 2026

Completamento primario (Effettivo)

30 aprile 2026

Completamento dello studio (Effettivo)

30 aprile 2026

Date di iscrizione allo studio

Primo inviato

15 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 luglio 2026

Primo Inserito (Effettivo)

20 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 luglio 2026

Ultimo verificato

1 marzo 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • Pulpal Condition

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi